Logo image of ASMB

ASSEMBLY BIOSCIENCES INC (ASMB) Stock Fundamental Analysis

NASDAQ:ASMB - Nasdaq - US0453962070 - Common Stock - Currency: USD

17.39  +0.25 (+1.46%)

After market: 17.39 0 (0%)

Fundamental Rating

2

ASMB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. While ASMB seems to be doing ok healthwise, there are quite some concerns on its profitability. ASMB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ASMB had negative earnings in the past year.
ASMB had a negative operating cash flow in the past year.
ASMB had negative earnings in each of the past 5 years.
ASMB had negative operating cash flow in 4 of the past 5 years.
ASMB Yearly Net Income VS EBIT VS OCF VS FCFASMB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

With a Return On Assets value of -40.31%, ASMB perfoms like the industry average, outperforming 56.45% of the companies in the same industry.
ASMB has a worse Return On Equity (-147.12%) than 62.19% of its industry peers.
Industry RankSector Rank
ROA -40.31%
ROE -147.12%
ROIC N/A
ROA(3y)-56.64%
ROA(5y)-51.96%
ROE(3y)-127.35%
ROE(5y)-96.95%
ROIC(3y)N/A
ROIC(5y)N/A
ASMB Yearly ROA, ROE, ROICASMB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ASMB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ASMB Yearly Profit, Operating, Gross MarginsASMB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

5

2. Health

2.1 Basic Checks

ASMB does not have a ROIC to compare to the WACC, probably because it is not profitable.
ASMB has more shares outstanding than it did 1 year ago.
ASMB has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ASMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ASMB Yearly Shares OutstandingASMB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
ASMB Yearly Total Debt VS Total AssetsASMB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ASMB has an Altman-Z score of -11.26. This is a bad value and indicates that ASMB is not financially healthy and even has some risk of bankruptcy.
ASMB has a Altman-Z score of -11.26. This is in the lower half of the industry: ASMB underperforms 75.81% of its industry peers.
There is no outstanding debt for ASMB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.26
ROIC/WACCN/A
WACC9.02%
ASMB Yearly LT Debt VS Equity VS FCFASMB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 2.05 indicates that ASMB has no problem at all paying its short term obligations.
With a Current ratio value of 2.05, ASMB is not doing good in the industry: 75.09% of the companies in the same industry are doing better.
ASMB has a Quick Ratio of 2.05. This indicates that ASMB is financially healthy and has no problem in meeting its short term obligations.
ASMB has a Quick ratio of 2.05. This is in the lower half of the industry: ASMB underperforms 72.94% of its industry peers.
Industry RankSector Rank
Current Ratio 2.05
Quick Ratio 2.05
ASMB Yearly Current Assets VS Current LiabilitesASMB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

ASMB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.79%, which is quite impressive.
Looking at the last year, ASMB shows a very strong growth in Revenue. The Revenue has grown by 148.33%.
The Revenue has been growing by 12.31% on average over the past years. This is quite good.
EPS 1Y (TTM)42.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.52%
Revenue 1Y (TTM)148.33%
Revenue growth 3Y65.83%
Revenue growth 5Y12.31%
Sales Q2Q%62.82%

3.2 Future

ASMB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.80% yearly.
Based on estimates for the next years, ASMB will show a decrease in Revenue. The Revenue will decrease by -6.92% on average per year.
EPS Next Y25.32%
EPS Next 2Y6.99%
EPS Next 3Y7.53%
EPS Next 5Y9.8%
Revenue Next Year4.22%
Revenue Next 2Y-14.15%
Revenue Next 3Y30.3%
Revenue Next 5Y-6.92%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ASMB Yearly Revenue VS EstimatesASMB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M
ASMB Yearly EPS VS EstimatesASMB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ASMB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ASMB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ASMB Price Earnings VS Forward Price EarningsASMB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ASMB Per share dataASMB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.99%
EPS Next 3Y7.53%

More info and screens

0

5. Dividend

5.1 Amount

ASMB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASSEMBLY BIOSCIENCES INC

NASDAQ:ASMB (6/20/2025, 8:16:02 PM)

After market: 17.39 0 (0%)

17.39

+0.25 (+1.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06
Inst Owners41.74%
Inst Owner Change-1.05%
Ins Owners10.27%
Ins Owner Change0.01%
Market Cap132.86M
Analysts82.22
Price Target32.3 (85.74%)
Short Float %0.2%
Short Ratio0.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.43%
Min EPS beat(2)24.55%
Max EPS beat(2)28.31%
EPS beat(4)4
Avg EPS beat(4)23.13%
Min EPS beat(4)12.95%
Max EPS beat(4)28.31%
EPS beat(8)6
Avg EPS beat(8)18.21%
EPS beat(12)6
Avg EPS beat(12)11.32%
EPS beat(16)10
Avg EPS beat(16)12.79%
Revenue beat(2)2
Avg Revenue beat(2)31.85%
Min Revenue beat(2)24.54%
Max Revenue beat(2)39.15%
Revenue beat(4)3
Avg Revenue beat(4)20.43%
Min Revenue beat(4)-22.37%
Max Revenue beat(4)40.39%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.86%
PT rev (3m)-10.8%
EPS NQ rev (1m)14.95%
EPS NQ rev (3m)25.41%
EPS NY rev (1m)13.38%
EPS NY rev (3m)35.64%
Revenue NQ rev (1m)-33.34%
Revenue NQ rev (3m)-23.39%
Revenue NY rev (1m)-25.33%
Revenue NY rev (3m)26.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.13
P/FCF N/A
P/OCF N/A
P/B 4.9
P/tB 4.9
EV/EBITDA N/A
EPS(TTM)-6.23
EYN/A
EPS(NY)-5.75
Fwd EYN/A
FCF(TTM)-7.36
FCFYN/A
OCF(TTM)-7.35
OCFYN/A
SpS4.21
BVpS3.55
TBVpS3.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.31%
ROE -147.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.64%
ROA(5y)-51.96%
ROE(3y)-127.35%
ROE(5y)-96.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.77%
Cap/Sales 0.04%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.05
Quick Ratio 2.05
Altman-Z -11.26
F-Score4
WACC9.02%
ROIC/WACCN/A
Cap/Depr(3y)32.95%
Cap/Depr(5y)216.9%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.52%
EPS Next Y25.32%
EPS Next 2Y6.99%
EPS Next 3Y7.53%
EPS Next 5Y9.8%
Revenue 1Y (TTM)148.33%
Revenue growth 3Y65.83%
Revenue growth 5Y12.31%
Sales Q2Q%62.82%
Revenue Next Year4.22%
Revenue Next 2Y-14.15%
Revenue Next 3Y30.3%
Revenue Next 5Y-6.92%
EBIT growth 1Y20.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6.57%
EBIT Next 3Y40.7%
EBIT Next 5Y2.97%
FCF growth 1Y30.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.1%
OCF growth 3YN/A
OCF growth 5YN/A